特立帕肽
虽然在一些小型成人试验中进行了研究，[29]Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012 Feb;97(2):391-9. [Erratum in: J Clin Endocrinol Metab. 2015 Jul;100(7):2800.]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275355/http://www.ncbi.nlm.nih.gov/pubmed/22090268?tool=bestpractice.com[30]Winer KK, Yanovski JA, Sarani B, et al. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab. 1998 Oct;83(10):3480-6.http://www.ncbi.nlm.nih.gov/pubmed/9768650?tool=bestpractice.com[31]Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone versus calcitriol and calcium. J Clin Endocrinol Metab. 2003 Sep;88(9):4214-20.https://academic.oup.com/jcem/article/88/9/4214/2845729http://www.ncbi.nlm.nih.gov/pubmed/12970289?tool=bestpractice.com 特立帕肽，又名人 PTH (1-34)，是截短的 PTH (1-84)，其药物代谢动力学和药物效应动力学特点均有所不同，目前还未被批准用于临床治疗甲状旁腺功能减退症。然而，它被批准用于治疗骨质疏松症。
